Journal Publications

[21]He Y., Le X., Hu G., Li Q., Chen Z. Discovery of Ureido-Based Apcin Analogues as Cdc20-specific Inhibitors against Cancer. Pharmaceuticals (Basel), 2023, 16(2).
[22]Hu L., Sun C., Kidd J.M., Han J., Fang X., Li H., Liu Q., May A.E., Li Q., Zhou L., Liu Q. A first-in-class inhibitor of Hsp110 molecular chaperones of pathogenic fungi. Nat Commun, 2023, 14(1): 2745.
[23]Li H., Hu L., Cuffee C.W., Mohamed M., Li Q., Liu Q., Zhou L., Liu Q. Correction: Interdomain interactions dictate the function of the Candida albicans Hsp110 protein Msi3. J. Biol. Chem., 2023, 299(2): 102879.
[24]Liu R., Chen Z., Hu G., Yu Z., Li Q., Liu D., Li L., Liu Z. A Novel PDK1/MEK Dual Inhibitor Induces Cytoprotective Autophagy via the PDK1/Akt Signaling Pathway in Non-Small Cell Lung Cancer. Pharmaceuticals (Basel), 2023, 16(2).
[25]Ma B., Cao Y., Qin J., Chen Z., Hu G., Li Q. Pulmonary artery smooth muscle cell phenotypic switching: A key event in the early stage of pulmonary artery hypertension. Drug Discov Today, 2023, 28(5): 103559.
[26]Qin J., Cao M., Hu X., Tan W., Ma B., Cao Y., Chen Z., Li Q., Hu G. Dual inhibitors of ASK1 and PDK1 kinases: Design, synthesis, molecular docking and mechanism studies of N-benzyl pyridine-2-one containing derivatives as anti-fibrotic agents. Eur J Med Chem, 2023, 247: 115057.
[27]Wu S., Xiao Z., Wei J., Zhang L., Cao Y., Chen Z., Li Q., Hu G. Imidazo[1,2-a]pyridine Derivatives as AMPK Activators: Synthesis, Structure-Activity Relationships, and Regulation of Reactive Oxygen Species in Renal Fibroblasts. ChemMedChem, 2023, 18(8): e202200696.
[28]Zhao C., Le X., Li M., Hu Y., Li X., Chen Z., Hu G., Hu L., Li Q. Inhibition of Hsp110-STAT3 interaction in endothelial cells alleviates vascular remodeling in hypoxic pulmonary arterial Hypertension model. Respir. Res., 2023, 24(1): 289.
[29]Chen Q., Le X., Li Q., Liu S., Chen Z. Exploration of inhibitors targeting KIF18A with ploidy-specific lethality. Drug Discov Today, 2024, 29(10): 104142.
[30]Hu X., Wu Y., Ouyang H., Wu J., Yao M., Chen Z., Li Q. Virtual Screening, Molecular Dynamics, and Mechanism Study of Homeodomain-Interacting Protein Kinase 2 Inhibitor in Renal Fibroblasts. Pharmaceuticals (Basel), 2024, 17(11): 1420.
[31]Hu Y., Zhao C., Tan W., Li M., Wang Y., Gao R., Chen Z., Jin Z., Hu L., Li Q. Discovery and Optimization of Hsp110 and sGC Dual-Target Regulators for the Treatment of Pulmonary Arterial Hypertension. J Med Chem, 2024, 67(15): 13474-13490.
[32]Li J., Gao R., Zhao C., Xiang H., Le X., Zhang X., Cai Q., He L., Li Q., Hu L., Zou H. Inhibition of breast cancer growth with AN-329, a novel Hsp110 inhibitor, by inactivating p-STAT3/c-Myc axis. Biomed. Pharmacother., 2024, 181: 117694.
[33]Li M., Zhao C., Xiang H., Wang Y., Gao R., Cai Q., Chen Q., Chen Z., Hu L., Li Q. Design, synthesis and optimization of pyrazolo[3,4-b] pyridine derivatives as Hsp110-STAT3 interaction disruptors for the treatment of pulmonary arterial hypertension. Bioorg Chem, 2024, 153: 107888.
[34]Wang Z., Liu L., Liu E., Chen R., Huang Y., Li Q. Carrier Polymer-Free Dissolvable Microneedles Enable Superhigh Drug Payload for Percutaneous Protein Delivery. ACS Materials Letters, 2024, 6(11): 4980-4987.
[35]Wu S., Zhang L., Hao C., Ma B., Li Z., Fan S., Li Q., Hu G., Chen Z. Chromone Derivatives as a Novel NOX4 Inhibitor: Design, Synthesis, and Regulation of ROS in Renal Fibroblast. Chem. Biol. Drug Des., 2024, 104(5): e70015.
[36]Zhang L., Yang X., Yi R., Wu S., Li Q., Hu G., Chen Z. Design, Synthesis, and Biological Evaluation of Quinoline (Quinolinone) Derivatives as NADPH Oxidase (NOX) Inhibitors. Chem. Biol. Drug Des., 2024, 104(2): e14610.
[37]Zhao C., Wu Y., Li M., Tan W., Hu Y., Wang Y., Gao R., Hu L., Li Q. Allosteric site identification, virtual screening and discovery of a sulfonamide Hsp110-STAT3 interaction inhibitor for the treatment of hypoxic pulmonary arterial hypertension. Eur J Med Chem, 2024, 279: 116855.
[38]Zhao C., Xiang H., Li M., Gao R., Zhang Y., Li Q., Hu L. Heat shock protein 110: A novel candidate for disease diagnosis and targeted therapy. Drug Discov Today, 2024, 29(12): 104199.
[39]Cao M., Guo Y., Tan W., Feng C., Chen Q., Yao M., Xu J., Chen Z., Li Q. Novel sodium-hydrogen exchanger 1 inhibitors with diphenyl ketone scaffold: Design, Synthesis, mechanism and evaluation in mice model of heart failure. Eur J Med Chem, 2025, 291: 117585.
[40]Chen Q., Le X., Wen Q., Cao S., Guo Y., Weng X., Zhang L., Wei J., Zou M., Hu L., Li Q., Liu S., Chen Z. Discovery of Cdc20/Hsp90 Dual-Target Inhibitors with Potent Antitumor Activity for Therapy of Acquired Resistant Melanoma. J Med Chem, 2025, 68(21): 22428-22454.

total68 2/4

first previous next last Page

李乾斌